Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid: a double-blind placebo-controlled cross-over phase IIIB study
Introduction - Epistaxis is the most frequent manifestation in hereditary hemorrhagic telangiectasia, in which no optimal treatment exists. It can lead to severe anemia and reduced quality of life. Positive effects of tranexamic acid, an antifibrinolytic drug, have been reported on epistaxis related...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
16 June 2014
|
| In: |
Thrombosis research
Year: 2014, Volume: 134, Issue: 3, Pages: 565-571 |
| ISSN: | 1879-2472 |
| DOI: | 10.1016/j.thromres.2014.06.012 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.thromres.2014.06.012 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0049384814003387 
|
| Author Notes: | Urban W. Geisthoff, Ulrich T. Seyfert, Marcus Kübler, Birgitt Bieg, Peter K. Plinkert, Jochem König |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1733104100 | ||
| 003 | DE-627 | ||
| 005 | 20230427102149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200916s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.thromres.2014.06.012 |2 doi | |
| 035 | |a (DE-627)1733104100 | ||
| 035 | |a (DE-599)KXP1733104100 | ||
| 035 | |a (OCoLC)1341359831 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Geisthoff, Urban Wilhelm |d 1968- |e VerfasserIn |0 (DE-588)118130587 |0 (DE-627)694697125 |0 (DE-576)291730981 |4 aut | |
| 245 | 1 | 0 | |a Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid |b a double-blind placebo-controlled cross-over phase IIIB study |c Urban W. Geisthoff, Ulrich T. Seyfert, Marcus Kübler, Birgitt Bieg, Peter K. Plinkert, Jochem König |
| 264 | 1 | |c 16 June 2014 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.09.2020 | ||
| 520 | |a Introduction - Epistaxis is the most frequent manifestation in hereditary hemorrhagic telangiectasia, in which no optimal treatment exists. It can lead to severe anemia and reduced quality of life. Positive effects of tranexamic acid, an antifibrinolytic drug, have been reported on epistaxis related to this disorder. We sought to evaluate the efficacy of treating nosebleeds in hereditary hemorrhagic telangiectasia with tranexamic acid. - Materials and Methods - In a randomized, double-blind, placebo controlled, cross-over phase IIIB study, 1 gram of tranexamic acid or placebo was given orally 3 times daily for 3months for a total of 6months. - Results - 22 patients were included in the intention-to-treat analysis. Hemoglobin levels, the primary outcome measure, did not change significantly (p=0.33). The secondary outcome measure was epistaxis score and patients reported a statistically significant reduction in nosebleeds, equaling a clinically relevant 54% diminution (p=0.0031), as compared to the placebo period. No severe side effects were observed. - Conclusion - Tranexamic acid reduces epistaxis in patients with hereditary hemorrhagic telangiectasia. (Clinical trial registration numbers: BfArM 141 CHC 9008-001 and ClinicalTrials.gov NCT01031992) | ||
| 650 | 4 | |a Antifibrinolytics | |
| 650 | 4 | |a Epistaxis | |
| 650 | 4 | |a Hereditary hemorrhagic telangiectasia | |
| 650 | 4 | |a Osler-Rendu-Weber syndrome | |
| 650 | 4 | |a Tranexamic acid | |
| 700 | 1 | |a Seyfert, Ulrich T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kübler, Marcus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bieg, Birgitt |e VerfasserIn |4 aut | |
| 700 | 1 | |a Plinkert, Peter K. |e VerfasserIn |0 (DE-588)1032658509 |0 (DE-627)739933043 |0 (DE-576)169008908 |4 aut | |
| 700 | 1 | |a König, Jochem |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thrombosis research |d Amsterdam [u.a.] : Elsevier Science, 1972 |g 134(2014), 3, Seite 565-571 |h Online-Ressource |w (DE-627)30671082X |w (DE-600)1500780-7 |w (DE-576)098253263 |x 1879-2472 |7 nnas |a Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid a double-blind placebo-controlled cross-over phase IIIB study |
| 773 | 1 | 8 | |g volume:134 |g year:2014 |g number:3 |g pages:565-571 |g extent:7 |a Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid a double-blind placebo-controlled cross-over phase IIIB study |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.thromres.2014.06.012 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0049384814003387 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200916 | ||
| 993 | |a Article | ||
| 994 | |a 2014 | ||
| 998 | |g 1032658509 |a Plinkert, Peter K. |m 1032658509:Plinkert, Peter K. |d 910000 |d 911000 |e 910000PP1032658509 |e 911000PP1032658509 |k 0/910000/ |k 1/910000/911000/ |p 5 | ||
| 999 | |a KXP-PPN1733104100 |e 3755845695 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Urban Wilhelm","role":"aut","display":"Geisthoff, Urban Wilhelm","family":"Geisthoff"},{"display":"Seyfert, Ulrich T.","family":"Seyfert","given":"Ulrich T.","role":"aut"},{"family":"Kübler","display":"Kübler, Marcus","given":"Marcus","role":"aut"},{"role":"aut","given":"Birgitt","display":"Bieg, Birgitt","family":"Bieg"},{"given":"Peter K.","role":"aut","display":"Plinkert, Peter K.","family":"Plinkert"},{"display":"König, Jochem","family":"König","role":"aut","given":"Jochem"}],"note":["Gesehen am 16.09.2020"],"title":[{"title":"Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid","subtitle":"a double-blind placebo-controlled cross-over phase IIIB study","title_sort":"Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid"}],"origin":[{"dateIssuedDisp":"16 June 2014","dateIssuedKey":"2014"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"physDesc":[{"extent":"7 S."}],"name":{"displayForm":["Urban W. Geisthoff, Ulrich T. Seyfert, Marcus Kübler, Birgitt Bieg, Peter K. Plinkert, Jochem König"]},"recId":"1733104100","id":{"eki":["1733104100"],"doi":["10.1016/j.thromres.2014.06.012"]},"relHost":[{"language":["eng"],"note":["Gesehen am 15.11.23"],"origin":[{"publisherPlace":"Amsterdam [u.a.]","dateIssuedDisp":"1972-","dateIssuedKey":"1972","publisher":"Elsevier Science"}],"title":[{"title_sort":"Thrombosis research","subtitle":"vascular obstruction, hemorrhage and hemostasis","title":"Thrombosis research"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"pages":"565-571","text":"134(2014), 3, Seite 565-571","year":"2014","volume":"134","extent":"7","issue":"3"},"disp":"Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid a double-blind placebo-controlled cross-over phase IIIB studyThrombosis research","id":{"zdb":["1500780-7"],"eki":["30671082X"],"issn":["1879-2472"]},"pubHistory":["1.1972 -"],"recId":"30671082X","physDesc":[{"extent":"Online-Ressource"}]}]} | ||
| SRT | |a GEISTHOFFUTREATMENTO1620 | ||